share_log

康方生物：關連交易有關收購康融東方股權的進一步資料

AKESO: CONNECTED TRANSACTION FURTHER INFORMATION IN RELATION TO ACQUISITION OF EQUITY INTEREST IN AD PHARMACEUTICALS

香港交易所 ·  Mar 4 07:35
Summary by Moomoo AI
康方生物科技（開曼）有限公司（「康方生物」）於2024年2月9日就其間接全資附屬公司作為買方，收購康融東方35%股權的交易，向潛在投資者及股東提供進一步資料。該交易的代價及付款條款是基於正常商業條款並經過公平磋商後確定。康方生物補充說明，在協定條款時，已考慮到賣方在康融東方的投資金額（人民幣185,000,000元）及其賬面價值（人民幣0元），以及康融東方旗下兩款新藥的研發階段等因素。該補充資料不影響先前公告的其他內容。
康方生物科技（開曼）有限公司（「康方生物」）於2024年2月9日就其間接全資附屬公司作為買方，收購康融東方35%股權的交易，向潛在投資者及股東提供進一步資料。該交易的代價及付款條款是基於正常商業條款並經過公平磋商後確定。康方生物補充說明，在協定條款時，已考慮到賣方在康融東方的投資金額（人民幣185,000,000元）及其賬面價值（人民幣0元），以及康融東方旗下兩款新藥的研發階段等因素。該補充資料不影響先前公告的其他內容。
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) on 9 February 2024, with its indirect wholly owned subsidiary as a buyer, acquired 35% shareholding in Hong Kong Oriental, providing further information to potential investors and shareholders. The price and payment terms of the transaction are determined on the basis of normal commercial terms and after fair consultation. Kangfang Biological Supplement states that the vendor's investment amount (RMB185,000,000) and its carrying value (RMB 0) and its carrying value (RMB 0) and the development phase of two new drugs under the auspices of CFU were taken into account in the agreement's terms. The supplemental information does not affect the rest of the previous announcement.
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) on 9 February 2024, with its indirect wholly owned subsidiary as a buyer, acquired 35% shareholding in Hong Kong Oriental, providing further information to potential investors and shareholders. The price and payment terms of the transaction are determined on the basis of normal commercial terms and after fair consultation. Kangfang Biological Supplement states that the vendor's investment amount (RMB185,000,000) and its carrying value (RMB 0) and its carrying value (RMB 0) and the development phase of two new drugs under the auspices of CFU were taken into account in the agreement's terms. The supplemental information does not affect the rest of the previous announcement.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more